Sudden Sensorineural Hearing Loss: A Diagnostic and Therapeutic Emergency

Andrew D. P. Prince, BA and Emily Z. Stucken, MD

The family physician’s role in recognizing and managing sudden sensorineural hearing loss (SSNHL) is crucial. A recently updated otolaryngologic clinical practice guideline has been released for this emergency syndrome, but dissemination is limited to a specialty journal. As a result, the guidelines may not be widely available in the primary care setting where patients often present. We provide this focused review to clarify and disseminate SSNHL guidelines for the frontline family physician. (J Am Board Fam Med 2021;34:216–223.)

Keywords: Audiology, Clinical Decision-Making, Conductive Hearing Loss, Family Medicine, Family Physicians, Otolaryngology, Primary Health Care, Sudden Hearing Loss

Introduction
Sudden sensorineural hearing loss (SSNHL) is a medical emergency in which patients experience a sudden (within 72 hours) drop in hearing that is sensorineural in nature, not the result of mechanical blockage from fluid or wax buildup. Prompt recognition is critical as there is a window of time in which medical interventions may be successful in restoring hearing and/or reducing tinnitus, thus providing significant improvement in patient quality of life. Although SSNHL can result from a variety of identifiable causes (neoplastic, infectious, autoimmune, neurologic, ototoxicity), 90% of cases are idiopathic.2–4 SSNHL affects 5 to 27 per 100,000 people annually, with about 66,000 new cases per year in the United States.4–7 The incidence, debilitating consequences of missed diagnosis and management, and the scarcity of randomized controlled trials led the American Academy of Otolaryngology–Head and Neck Surgery to develop a clinical practice guideline (CPG) that was recently updated in 2019 to assist providers in appropriately managing this condition.7,8

The CPG for SSNHL is intended for all clinicians who diagnose or manage patients aged 18 years and older that present with sudden hearing loss. The CPG is focused specifically on idiopathic SSNHL—hearing loss that is rapid in onset, not due to conductive pathology, and not explained by an identifiable cause. Despite intense efforts to disseminate CPGs, previous studies have shown that uptake of recommendations in CPGs is limited and adherence to certain key action statements is low.9–11 The need to disseminate the guidelines beyond the otolaryngology community is crucial, as the majority of patients with SSNHL are first evaluated by nonotolaryngologists, with 15,000 to 66,000 patients visiting family medicine clinics, urgent care centers, and emergency rooms for assessment of this complaint annually.7 To our knowledge, this is the first report specifically aimed at disseminating the guidelines for SSNHL into the family medicine literature, with a goal of achieving broader adherence to the CPG.

The family physician’s role in recognizing and managing SSNHL is pivotal. In their role at the frontline, family physicians can provide the highest quality assessment, management, and patient-centered care. Timely recognition of SSNHL by the initial evaluating physician affects the availability of treatment options, as well as the success rates of treatment. Improved awareness, clarity, and dissemination of CPGs is critical to improve adherence and the quality of clinical care.7,10 We describe a case report of a typical patient presenting with SSNHL, followed by a summary of the

This article was externally peer reviewed.
Submitted 6 May 2020; revised 25 July 2020; accepted 30 July 2020.
From the University of Michigan Medical School, Ann Arbor, MI (ADPP); Department of Otolaryngology–Head and Neck Surgery, University of Michigan, Ann Arbor, MI (EZS).
Funding: None.
Conflict of interest: None.
Corresponding author: Andrew D. P. Prince, BA, University of Michigan Medical School, 1301 Catherine St, Ann Arbor, MI 48109 (E-mail: adprince@umich.edu).
current CPG to equip the frontline family physicians with tools for managing sudden hearing loss.

Case Report
A 64-year-old man with hypertension presents to his family medicine physician complaining of blocked hearing in his left ear for 1 day. He noticed a loud ringing sound and the feeling of the left ear being plugged. He has not had any dizziness, pain in his ear, or drainage from his ear. He denies any recent trauma, noise exposures, respiratory illness, change in medications, or other neurologic symptoms.

On physical examination, the left external ear and ear canal are unremarkable. The left tympanic membrane is normal in appearance and no definite middle ear effusion can be seen. A vibrating 512-Hz tuning fork placed on the midline of the forehead is perceived louder in the right ear. Cranial nerve examination is otherwise intact, and there are no other abnormalities noted on a complete head and neck examination nor focal neurological examination.

The family physician is concerned that the patient may be experiencing SSNHL and discusses the diagnosis, natural history, treatment options, and current evidence regarding this condition. The patient and physician jointly decide to try a course of oral steroids as initial therapy, and the patient is prescribed 60 mg prednisone daily for 10 days, followed by a 7-day taper. The family physician also orders magnetic resonance imaging (MRI) brain/internal auditory canal protocol with gadolinium and places an urgent referral to an otolaryngologist for a hearing test and further evaluation.

The otolaryngology office schedules the patient for an urgent audiogram and evaluation by an otolaryngologist the following day. The audiogram demonstrates a significant drop in sensorineural hearing levels throughout the frequency spectrum. After discussion, the patient elects to complete his oral steroid therapy before any further intervention is taken. He has a partial response to therapy 2 weeks after onset of symptoms, and he elects to undergo an intratympanic (IT) injection at this time. At followup 1 week later, his hearing has returned to his baseline level.

CPGs for SSNHL
The guidelines discussed below were adapted from S. Chandrasekhar, B. Tsai Do, S. Schwartz et al, Clinical Practice Guideline: Sudden Hearing Loss (Update), Otolaryngology–Head and Neck Surgery.
fluid, otitis externa, tympanic membrane abnormalities, trauma, and cholesteatoma. Unlike CHL, patients with SSNHL will almost always have a normal otoscopic examination.\(^7\) The authors acknowledge, however, that definitive otoscopic diagnosis of a middle-ear effusion may be challenging in some situations and encourage the addition of a tuning fork test to distinguish between CHL and SNHL when audiometric data are not readily available. In general, the tuning fork evaluations provide a reliable method to acutely assess the type of hearing loss and are supported by the CPG.\(^7,8\) Figure 2 demonstrates proper tuning fork technique and result interpretation. Ahmed et al.\(^{21}\) proposed the hum test as an alternative to the Weber tuning fork test with similar sensitivity and specificity. This test can be used without a tuning fork by asking the patient to hum; if he or she hears one’s own hum louder in the affected ear, there is likely CHL in that ear. A complete history and targeted physical examination with tuning fork testing are essential but do not supplant formal audiometric testing.

**Labs, Imaging, and Audiometry**

Though most SSNHL is idiopathic, there are several other possible etiologies to consider. CPG guidelines strongly recommend against (Grade B) routine, “shotgun,” laboratory workup as the evidence supporting their use is limited to observational and case-control studies.\(^7\) Within the literature most studies are underpowered and none support that a laboratory test improves management or outcomes.\(^8,22-24\) Furthermore, labs have associated cost and potential harms related to false-positive or false-negative results. Laboratory studies should be
limited to specific tests cued by pertinent findings in the history or physical examination.

It is recommended (Grade C) that an audiometric evaluation is obtained for SSNHL, or a referral made to a physician that can obtain one, within 14 days of presentation and for serial evaluations. Audiometry is the most reliable evaluation for differentiating CHL from sensorineural hearing loss and establishes frequency-specific hearing and word recognition ability. There may be concern regarding the logistic ability for a patient to undergo an audiometric evaluation within the specified time frame. To address this, most, otolaryngology practices have a specific workflow to triage referrals for sudden hearing loss and assure that these patients are seen promptly.

Imaging is an important adjunct to SSNHL workup and choosing the most effective modality is key. Routine computed tomography of the head is strongly recommended against (Grade B) in the initial assessment of patients with presumptive idiopathic SSNHL without focal neurologic findings. A routine head computed tomography scan is a very low-yield study for examination of the inner ear, and yet is often

| Table 1. Nonidiopathic Causes of Sudden Sensorineural Hearing Loss |
|----------------------|------------------------------------------------------------------|
| Causes               | Diagnosis                                                        |
| Infections           | Herpesviruses, influenza, measles, mumps, rubella, human immunodeficiency virus, Lyme disease, meningitis |
| Ototoxic drugs       | Aminoglycosides, vancomycin, erythromycin, loop diuretics, antimalarials, cisplatin, sildenafil, cocaine |
| Neoplasms            | Vestibular schwannoma, meningioma, intracranial metastases, lymphoma, leukemia, plasma cell dyscrasia |
| Trauma               | Head injury, barotraumas, noise exposure                          |
| Autoimmune disease   | Cogan’s syndrome, susac syndrome, systemic lupus erythematosus; rheumatoid arthritis, sjögren’s syndrome, vasculitides |
| Vascular disorder    | Vertebrobasilar cerebrovascular accident or transient ischemic attack, cerebellar infarction, inner ear hemorrhage |
| Various causes       | Meniere’s disease, otosclerosis, Paget’s disease, multiple sclerosis, sarcoidosis, hypothyroidism |

Figure 2. Recommended technique and result interpretation for Weber and Rinne testing.
ordered. It is recommended (Grade B) to obtain an MRI to evaluate for alternate pathologies involving the pathway from the cochlea through the brainstem commonly referred to as “retrocochlear pathology.” Vestibular schwannomas are the most frequent mass lesion discovered in cases of SSNHL, with an incidence of 2.5%. 

An MRI is the standard and we advise the sensitive and widely available internal auditory canal protocol MRI with gadolinium enhancement. Auditory brainstem response (Grade C) may be offered for patients with SSNHL who do not wish to have an MRI. However, a normal auditory brainstem response is less sensitive than MRI and may miss small tumors.

Management
A shared decision-making approach to management and developing a plan of care for patients with SSNHL is important. There are a myriad of inconclusive or modestly beneficial treatment options ranging from observation to combination modality steroid therapy. The CPG strongly recommends (Grade B) educating patients about the favorable natural history, benefits, and risks of interventions, and the limitations of existing evidence. Despite the intuitiveness of this recommendation, it is one of the most frequently skipped by otolaryngologists and nonotolaryngologists alike. We encourage practitioners to reference the CPG, which provides a useful patient education handout titled, “Frequently Asked Questions/Patient Education.”

A widely used treatment of idiopathic SSNHL is administration of corticosteroids, either oral or IT. The CPG provides the option (Grade C) to use corticosteroids as initial therapy to patients with SSNHL within 2 weeks of symptom onset. Historically, systemic steroids have been utilized by clinicians because steroid administration is one of the few treatment options that has shown efficacy, despite mostly equivocal data. Systemic steroid therapy may be contraindicated in cases of insulin-dependent or poorly controlled diabetes, tuberculosis, or peptic ulcer disease. Treatment with corticosteroids seems to offer the greatest recovery when initiated in the first 2 weeks following SSNHL, with little benefit after 4 to 6 weeks; this is similar to the timeline of spontaneous improvement in hearing, making it difficult to conclude corticosteroids offer greater benefit than observation alone. IT steroid administration was first described for SSNHL in 1996. IT steroid use is increasing in popularity due to a reduction in systemic side effects. IT injections may be offered either as primary therapy for SSNHL, in combination with systemic steroids as primary therapy, or as salvage therapy after a patient has failed an initial course of systemic steroids. The 2019 CPG does not make a specific recommendation on route of administration (systemic, IT, or combination therapy) for primary treatment. This differs from salvage therapy, which will be discussed separately.

If an IT steroid injection is selected, this procedure is performed in the clinic setting by an otologist or general otolaryngologist comfortable with the procedure. It can be performed at the initial visit to an otolaryngologist’s office, without the need for special scheduling. This procedure is performed under otomicroscopic guidance and entails direct topical anesthesia of the tympanic membrane (no systemic sedation or anesthesia is administered), followed by a controlled puncture of the tympanic membrane to instill a liquid steroid formulation to the middle ear space. IT injections provide a high concentration of steroid to the inner ear by diffusion through the round window membrane, while minimizing systemic absorption. Multiple trials, reviews, and meta-analyses have yet to show any significant difference in therapeutic outcomes between systemic therapy, IT, and combination therapy (with the exception of the Battaglia study, which suggested that initial therapy with IT steroids, either alone or in combination with oral steroids, conferred benefit over systemic steroids alone). Ultimately, when you consider the devastating effects of SSNHL to patients, even a small possibility of hearing improvement makes corticosteroids a reasonable treatment to offer patients.

If systemic steroids are chosen for initial treatment, they should be given within 14 days. The recommended dose of oral prednisone is 1 mg/kg/day in a single (not divided) dose, with the usual maximum dose of 60 mg daily prescribed for 7 to 14 days, then tapered over a similar period of time. The equivalent dose of prednisone (60 mg) is 48 mg for methylprednisolone and 10 mg for dexamethasone. Early treatment is of the utmost importance, and adequate initial dosing is important, with avoidance of the methylprednisolone and prednisone dose packs, which do not provide adequate steroid dose for this indication. Serious side effects should be closely monitored including blurred vision, glaucoma, weight gain, muscle weakness, osteoporosis, susceptibility to infections, worsening of diabetes, and the limitations of existing evidence.
and hypertension. The CPG does not specify which provider should initiate steroid therapy. If the history and physical examination strongly suggest SSNHL, and there are no contraindications present, it is most prudent for the initial provider to begin the treatment regimen, given the time-sensitive nature of response-to-therapy.

Among the other initial treatment options available, the CPG strongly recommends against (Grade B) routine prescription of antivirals, thrombolytics, vasodilators, or vasoactive substances to patients with SSNHL. Studies examining antiviral, vasoactive, vasodilatory, and rheologic agents have been inconclusive, revealed no significant benefit, or pose significant side effects. Less frequently implemented in the United States is the option (Grade B) to refer to a clinician who can provide hyperbaric oxygen therapy (HBOT) combined with steroid therapy within 2 weeks of onset, or as salvage therapy within 1 month of the onset of SSNHL. The therapy is not currently approved by the U.S. Food and Drug Administration, but there have been multiple trials and reviews that demonstrated potential benefit.

When initial therapy fails, guidelines recommend (Grade B) IT steroid therapy for incomplete recovery from SSNHL 2 to 6 weeks after the onset of symptoms. Salvage therapy refers to failure of systemic or topical steroids, HBOT, or observation. Data suggests that IT steroids are an effective modality for salvage therapy. Conflicting and weak data exists for the use of systemic steroids and HBOT alone, or as combination with IT for salvage therapy.

Patient reported hearing recovery is not an accurate measure of response to treatment. Audiometric evaluation is recommended (Grade C) for all patients with SSNHL at the conclusion of treatment and within 6 months of treatment completion. Longitudinal followup is important as some patients (close to one third) will have an underlying cause that is eventually identified but was not evident at initial presentation. In addition, the patient with partial or no hearing recovery and/or persistent tinnitus will require ongoing management from otolaryngologic, audiological, and psychological perspectives. If there is residual or permanent hearing loss and/or tinnitus, it is strongly recommended (Grade B) that clinicians counsel patients about the possible benefits of audiologic rehabilitation and other supportive measures. There are a variety of further management options for SSNHL sequela that start with appropriate patient centered counseling and decision making. Besides counseling, some patients require therapeutic interventions such as speech reading, and auditory training. Further data-supported measures include hearing aids, hearing-assist devices, and cochlear implantation, which may rehabilitate hearing and quality of life.

Conclusion
The family physician is often the initial provider to interface with patients who present with SSNHL. The family medicine provider plays a crucial role in the early recognition and initial management of SSNHL. A thorough history and physical examination are the cornerstones of evaluation to differentiate between sudden CHL and SNHL, and to assess for important neurologic diagnosis such as stroke. Prompt initiation of steroid therapy is recommended for patients with SSNHL, along with MRI imaging, audiology evaluation, and consultation with an otolaryngologist. We encourage the family physician to feel empowered to begin initial therapy with oral corticosteroids if their suspicion for SSNHL is high, even while awaiting formal audiometric confirmation or referral to a specialist.

To see this article online, please go to: http://jabfm.org/content/34/1/216.full.

References

1. Dallan I, Fortunato S, Casani A, et al. Long-term follow up of sudden sensorineural hearing loss patients treated with intratympanic steroids: audiologic and quality of life evaluation. J Laryngol Otol 2014;128:669–73.
2. Rauch S. Idiopathic sudden sensorineural hearing loss. N Engl J Med 2008;359:833–40.
3. Stew B, Fishpool S, Williams H. Sudden Sensorineural hearing loss. Brit J Hosp Med 2012;73:86–9.
4. Alexander T, Harris J. Incidence of sudden sensorineural hearing loss. Otol Neurotol 2013;34:1586–9.
5. Mattoo D, Simmons F. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 1977;86:463–80.
6. Byl F. Seventy-six cases of presumed sudden hearing loss occurring in 1973: prognosis and incidence. Laryngoscope 1977;87:817–25.
7. Chandrasekhar S, Tsai Do B, Schwartz S, et al. Clinical practice guideline: sudden hearing loss (update). Otolaryngol Head Neck Surg 2019;161:195–210.
8. Stachler R, Chandrasekhar S, Archer S, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg 2012;146:S1–S35.

9. Cabana M, Rand C, Powe N, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458–65.

10. Ryan M. Adherence to clinical practice guidelines. Otolaryngol Head Neck Surg 2017;157:548–50.

11. Witsell D, Khoury T, Schulz K, et al. Evaluation of compliance for treatment of sudden hearing loss: a CHEER Network study. Otolaryngol Head Neck Surg 2016;155:48–55.

12. Federspil P. Drug-induced sudden hearing loss and vestibular disturbances. Adv Otorhinolaryngol 1981;27:144–58.

13. Govindaraju R, Omar R, Rajagopalan R, Norlisah R, Kwan-Hoong N. Hearing loss after noise exposure. Auris Nasus Larynx 2011;38:519–22.

14. Norris C. Drugs affecting the inner ear: a review of their clinical efficacy, mechanisms of action, toxicity, and place in therapy. Drugs 1988;36:754–72.

15. Saunders J, Luxford W, Devgan K, Fetterman B. Sudden hearing loss in acoustic neuroma patients. Otolaryngol Head Neck Surg 1995;113:23–31.

16. Tunkel D, Bauer C, Sun G, et al. Clinical practice guideline: tinnitus. Otolaryngol Head Neck Surg 2014;151:S1–S40.

17. Niu X, Zhang Y, Zhang Q, et al. The relationship between hearing loss and vestibular dysfunction in patients with sudden sensorineuronal hearing loss. Acta Otolaryngol 2016;136:225–31.

18. Chiossoine-Kerdel J, Baguley D, Stoeklart R, Moffat D. An investigation of the audiologic handicap associated with unilateral sudden sensorineuronal hearing loss. Am J Otol 2000;21:645–51.

19. Rosenfeld R, Shin J, Schwartz S, et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngol Head Neck Surg 2016;154:S1–S41.

20. Schwartz S, Magit A, Rosenfeld R, et al. Clinical practice guideline (update): earwax (cerumen impaction). Otolaryngol Head Neck Surg 2017;156:S1–S29.

21. Ahmed O, Gallant S, Ruiz R, et al. Validity of the hum test, a simple and reliable alternative to the Weber test. Ann Otol Rhinol Laryngol 2018;127:402–5.

22. Conte G, Berardino D, Sina C, et al. MR imaging in sudden sensorineuronal hearing loss: time to talk. AJNR Am J Neuroradiol 2017;38:1475–9.

23. Abele T, Besachio D, Quigley E, et al. Diagnostic accuracy of screening MR imaging using enhanced axial CISS and coronal T2WI for detection of small internal auditory canal lesions. AJNR Am J Neuroradiol 2014;35:2366–70.

24. Chandrasekhar S, Brackmann D, Devgan K. Utility of auditory brainstem response audiometry in diagnosis of acoustic neuromas. Am J Otol 1995;16:63–7.

25. Schmidt R, Sataloff R, Newman J, Spiegel J, Myers D. The sensitivity of auditory brainstem response testing for the diagnosis of acoustic neuromas. Arch Otolaryngol Head Neck Surg 2001;127:19–22.

26. Haynes DS, O’Malley M, Cohen S, Watford K, Labadie RF. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2007;117:3–15.

27. Chen C, Halpin C, Rauch S. Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis. Otol Neurotol 2003;24:728–33.

28. Silverstein H, Choo D, Rosenberg SI, Kuhn J, Seidman M, Stein I. Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat J 1996;75:468–71.

29. Spear S, Schwartz S. Intratympanic steroids for sudden sensorineural hearing loss: a systematic review. Otolaryngol Head Neck Surg 2011;145:534–43.

30. Parnes L, Sun A, Freeman D. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed-up by clinical application. Laryngoscope 1999;109:1–17.

31. Chandrasekhar S. Intratympanic dexamethasone for sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Laryngoscope 2015;125:209–17.

32. Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2016;154:S1–S41.

33. Ahn HJ, Han WM, Kim HJ, Chung WJ, Yoon TH. Therapeutic effectiveness over time of intratympanic dexamethasone as salvage treatment of sudden deafness. Acta Otolaryngol 2008;128:128–31.

34. Crane R, Camilon M, Nguyen S, Meyer T. Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Laryngoscope 2015;125:209–17.

35. Garavello W, Galluzzi F, Gainer R, Zanetti D. Intratympanic steroid treatment for sudden deafness: a meta-analysis of randomized controlled trials. Otol Neurotol 2012;33:724–9.

36. Mirian C, Oveseen T. Intratympanic vs systemic corticosteroids in first-line treatment of idiopathic sudden sensorineural hearing loss. JAMA Otolaryngol Head Neck Surg 2020;146:421–428.

37. Lim HJ, Kim YT, Choi SJ, et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective randomized trial. Otolaryngol Head Neck Surg 2013;148:121–7.

38. Rauch SD, Halpin CF, Antonelli PJ, et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA 2011;305:2071–9.
39. Kavita S, Dinesh S, Jatinder S. Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. J Basic Clin Physiol Pharmacol 2016;27:371–7.

40. Ahn JH, Yoo MH, Yoon TH, Chung JW. Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness? Laryngoscope 2008;118:279–82.

41. Fisch U, Nagahara K, Pollak A. Sudden hearing loss: circulatory. Am J Otol 1984;5:488–91.

42. Li Y. Interventions in the management of blood viscosity for idiopathic sudden sensorineural hearing loss: a meta-analysis. J Health Res Rev 2017;4:50–61.

43. Gill A, Bell C. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. QJM 2004;97:385–95.

44. Bennett M, Kertesz T, Perleth M, Yeung P, Lehm J. Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane Database Syst Rev 2012;10:CD0043739.

45. Yang C, Wu R, Hwang C. Comparison of intratympanic steroid injection, hyperbaric oxygen and combination therapy in refractory sudden sensorineural hearing loss. Otol Neurotol 2013;34:1411–6.

46. Moon I, Lee J, Kim J, Hong S, Lee W. Intratympanic dexamethasone is an effective method as a salvage treatment in refractory sudden hearing loss. Otol Neurotol 2011;32:1432–6.

47. de Oliveira Penido N, Ramos HVL, Barros FA, Cruz OLM, Toledo RN. Clinical, etiological and progression factors of hearing in sudden deafness. Brazil J Otorhinolaryngol 2005;71:633–8.

48. Hol M, Bosman A, Snik A, Mylauus E, Creemers C. Bone-anchored hearing aids in unilateral inner ear deafness: an evaluation of audiometric and patient outcome measurements. Otol Neurotol 2005;26:999–1006.

49. Blasco M, Redleaf M. Cochlear implantation in unilateral sudden deafness improves tinnitus and speech comprehension: meta-analysis and systematic review. Otol Neurotol 2014;35:1426–32.

50. Gaylor JM, Raman G, Chung M, et al. Cochlear implantation in adults: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg 2013;139:265–72.